Animal mRNA Vaccine Technology Solutions

Your Partner in Animal mRNA Vaccine Development and Manufacturing

Areterna’s cutting-edge mRNA vaccine platform drives the development of innovative, cost-effective, and highly customizable veterinary vaccines. We provide comprehensive services encompassing sequence design, mRNA vaccine manufacturing, LNP formulation, analytical testing, and pre-clinical testing to address the evolving challenges of animal diseases.

Comprehensive Solution for Animal mRNA Vaccines

Areterna has years of experience developing veterinary mRNA vaccines with vaccine candidates, such as RV, IBRV, BVDV, PRRSV, PEDV, FMDV, PRV, FIPV, FCV, FPV, and FHV. 

  • Vaccine Candidate Development

Design mRNA sequences for antigens specific for prevailing viral strains. To enhance immune response, these mRNA constructs can include multiple antigens, antigen mutations, signaling peptides and co-stimulatory signals. Our proprietary algorithms then optimize the entire sequence—from UTRs, CDS, to the cap and poly-A tail—ensuring maximum protein expression.

  • Biological Validation

Including Immunofluorescence (IF) assay, Immunoblotting (WB) assay, Flow cytometry (FCM) assay, and etc.

  •  mRNA Synthesis / LNP Encapsulation / Analytical Development

We have the capability to conduct IVT synthesis in-house, along with comprehensive process development. We can perform full panel QC testing on plasmid DNA, mRNA and LNP. Our analytical team can develop construct-specific assays such as LC-MS based capping and tailing assay. We have high-resolution Mass Spec on site as well as Zetasizer and HPLC-CAD to support LNP testing.

  • Pre-clinical Testing and Development

 

 Fill out the form to download a free digital copy INSTANTLY!

Why Choose Areterna to Support Your Animal mRNA Vaccine Development?

At Areterna, we offer end-to-end solutions by manufacturing mRNA vaccines and conducting pre-clinical testing under one roof. This eliminates the need to engage separate companies for manufacturing and testing, streamlining the entire process. With years of experience and hundreds of mRNA vaccine candidates developed, we have the expertise you can rely on. Additionally, since we produce mRNA raw materials in-house, we have greater control over both costs and project timelines.

Our novel cap analogs bypass third-party IP, providing a strategic advantage. Additionally, our low-cost GMP-grade cap analogs and NTPs contribute to significant vaccine cost reduction.

With years of experience in mRNA sequence design and optimization, we specialize in creating highly effective mRNA constructs tailored to specific therapeutic needs.

Extensive capability and experience in LNP formulation development, enabling the creation of efficient and targeted delivery systems for various therapeutic applications.

We have the capability to conduct comprehensive pre-clinical testing in both cells and animal models, ensuring thorough evaluation of efficacy and safety before advancing to clinical trials.

Our BSL-3 lab is equipped to safely handle infectious agents, allowing us to test the performance of mRNA vaccines against high-risk pathogens in controlled environments.